UK regulator warns of small but severe risk of pancreatitis from weight-loss jabs
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning about the potential risk of severe acute pancreatitis associated with weight-loss medication. According to recent data, approximately 1.6 million adults in England, Wales, and Scotland used GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), which are used to lose weight.
The MHRA has updated its guidance following an increase in reports of acute pancreatitis, a condition where the pancreas suddenly becomes inflamed. This can cause severe abdominal pain, nausea, fever, and even hospitalization. The regulator acknowledges that while pancreatitis is rare, it's essential for patients to be aware of this potential side effect.
The data shows that 1,143 reports of acute and chronic pancreatitis have been logged among patients taking semaglutide or tirzepatide, with 17 reported fatalities. Nearly all (973) were related to tirzepatide, while 166 were linked to semaglutide. The MHRA has also received fewer reports from patients taking liraglutide and dulaglutide.
The agency's chief safety officer, Dr Alison Cave, emphasized that the risk of developing severe side effects is "very small" but stressed the importance of being aware of associated symptoms. She advised patients to report any concerns to their healthcare professional and the MHRA's yellow card scheme.
A spokesperson for Novo Nordisk, which makes Wegovy and Ozempic, said that patient safety is a top priority and recommended that patients take these medications only as prescribed by a healthcare professional. Eli Lilly, the manufacturer of Mounjaro, also emphasized its commitment to patient safety and encouraged users to consult their doctor if they experience any side effects.
The MHRA's efforts to monitor medication safety are ongoing, with a new study launched to investigate whether an individual's genes can influence the risk of pancreatitis. This study aims to help identify patients who may be most at risk of adverse reactions and prescribe safer medicines accordingly.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning about the potential risk of severe acute pancreatitis associated with weight-loss medication. According to recent data, approximately 1.6 million adults in England, Wales, and Scotland used GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), which are used to lose weight.
The MHRA has updated its guidance following an increase in reports of acute pancreatitis, a condition where the pancreas suddenly becomes inflamed. This can cause severe abdominal pain, nausea, fever, and even hospitalization. The regulator acknowledges that while pancreatitis is rare, it's essential for patients to be aware of this potential side effect.
The data shows that 1,143 reports of acute and chronic pancreatitis have been logged among patients taking semaglutide or tirzepatide, with 17 reported fatalities. Nearly all (973) were related to tirzepatide, while 166 were linked to semaglutide. The MHRA has also received fewer reports from patients taking liraglutide and dulaglutide.
The agency's chief safety officer, Dr Alison Cave, emphasized that the risk of developing severe side effects is "very small" but stressed the importance of being aware of associated symptoms. She advised patients to report any concerns to their healthcare professional and the MHRA's yellow card scheme.
A spokesperson for Novo Nordisk, which makes Wegovy and Ozempic, said that patient safety is a top priority and recommended that patients take these medications only as prescribed by a healthcare professional. Eli Lilly, the manufacturer of Mounjaro, also emphasized its commitment to patient safety and encouraged users to consult their doctor if they experience any side effects.
The MHRA's efforts to monitor medication safety are ongoing, with a new study launched to investigate whether an individual's genes can influence the risk of pancreatitis. This study aims to help identify patients who may be most at risk of adverse reactions and prescribe safer medicines accordingly.